262.1 Guardian of renal harmony: Unraveling the ıntricacies of CD47 expression in allograft rejection and graft survival
Dr. Merih Tepeoglu, Turkey
262.2 Blocking CXCL10-CXCR3-mediated macrophages can reduce the antibody-mediated rejection of renal transplantation
Dr. Bingxuan Zheng, People's Republic of China
262.3 Intragraft gene transcript changes with intravenous immunoglobulin therapy versus standard care in chronic antibody mediated rejection- vipar study cohort
Dr. Dhakshayini Tharmaraj, Australia
262.4 Anti-HLA Donor-Specific Antibody Pretransplant Assessment Impact on Long-Term Outcomes After Kidney Transplantation
Mrs. Cristina Glehn, Brazil
262.5 Effectiveness of the Treatment of Antibody Mediated Rejection- a Real-World evidence study
Dr. Gillian Divard, France
262.6 Absolute dd-cfDNA monitoring reduces time to ABMR diagnosis in kidney transplant recipients with de novo DSA: a diagnostic randomized clinical trial
Dr. Aylin Akifova, Germany
262.7 Unexpected role of programmed death-ligand 1 (PD-L1) in renal allografts with antibody-mediated rejection
Prof. Binnaz Handan Ozdemir, Turkey
262.8 Correlation of early ultrastructural findings, microvascular HLA-DR, and VEGF expression in renal allografts with acute rejection types: Impact on transplant glomerulopathy and interstitial fibrosis
Dr. Eda Yilmaz Akcay, Turkey
262.9 The Clinical Utility of Follow-up Allograft Biopsies After Early Acute TCMR In Renal Transplantation